In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alfred Mann: Boundless Innovator

Executive Summary

An interview with Alfred Mann, one of the device industry's most remarkable innovators, whose extraordinary technological and commercial successes extend from cardiology to cochlear implants to neurostimulation, and who is now looking to succeed where others have failed with inhaled insulin.

You may also be interested in...

Top Device Stories of the Decade

A look back at the biggest devices stories of the decade, in capsule form.

Financings Of The Fortnight: Follow-On Fever

Does the recent rash of follow-on public offerings mean biotech IPOs are around the corner? Recent financings provide reason to think it's possible.

Inhaled Insulin’s Last True Believer: An Interview with Alfred Mann

The following is an excerpt from an 1interview with Mannkind founder Alfred Mann, published in the September issue of FDC-Windhover's IN VIVO. Mann explains his conviction that inhaled insulin will be a blockbuster product - despite the commercial failure of Exubera and the decision of other sponsors to drop development of other versions.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts